Author

Yujie Li

Institution: Qilu Pharmaceutical Co., Ltd. (China)

Observed institutions: China Academy of Chinese Medical Sciences, Lee's Pharmaceutical (China), Institute of Chinese Materia Medica, Qilu Pharmaceutical Co., Ltd. (China)

ORCID: 0000-0002-2325-0390

Observed ORCID: 0000-0002-2325-0390

OpenAlex ID: A5034972053

Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2022 · Jusheng An, Jie Tang, et al. · Clinical Cancer Research · 34

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.

2025 · Yakun Wang, Jifang Gong, et al. · Journal of Clinical Oncology · 11

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma

2024 · Bixia Tang, Jun Xiao, et al. · The Oncologist · 5

Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial

2024 · Rongbo Lin, Binbin Song, et al. · BMC Palliative Care · 4

MicroRNA-32-5p inhibits metastasis by directly targeting VPS4B and increases sensitivity to dihydroartemisinin in neuroblastoma

2024 · Lina Chen, Hui Liu, et al. · Science of Traditional Chinese Medicine · 4

Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin’s lymphoma

2024 · Ningjing Lin, Chuan He, et al. · Journal of Cancer Research and Therapeutics · 1

Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2025 · Jusheng An, Jie Tang, et al.

Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2025 · Jusheng An, Jie Tang, et al.

Data from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2023 · Jusheng An, Jie Tang, et al.

Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2023 · Jusheng An, Jie Tang, et al.

Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2023 · Jusheng An, Jie Tang, et al.

Data from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

2023 · Jusheng An, Jie Tang, et al.

Works count: 12

Citation count: 59

H-index: 4

I10-index: 2